- Six-month data from PaTH Forward open-label extension support potential use of TransCon PTH as a hormone replacement therapy for adult hypoparathyroidism – - Conference call Tuesday, September 29 at ...
77.6% of patients treated with palopegteriparatide in the PaTHway China Trial achieved the primary multi-component endpoint compared to 0.0% for placebo (p <0.0001) Palopegteriparatide was generally ...
COPENHAGEN, Denmark, July 14, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (ASND) today announced new data from Week 156 of its Phase 3 PaTHway Trial confirming that long-term treatment with TransCon ...
The information provided in response to the FDA’s Complete Response Letter "constituted a major amendment to the NDA" requiring more time for review. The Food and Drug Administration (FDA) has ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Palopegteriparatide improved skeletal dynamics and renal ...
People can use methods such as dietary changes, supplements, diuretics, and hormone replacement to manage low parathyroid hormone levels. Hypoparathyroidism is a rare condition in which the ...
Bones, although composing the hardest tissue in the human body, are not stagnant structures. According to recent studies, bones maintain a lively metabolism and closely interact via nerves with the ...
SHANGHAI, Aug. 12, 2024 /PRNewswire/ -- VISEN Pharmaceuticals, an innovative biopharmaceutical company focused on endocrine diseases, today announced topline data from the 26-week randomized, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback